https://www.bioqubeventures.com/egle-therapeutics-to-highlight-novel-preclinical-findings-for-regulatory-t-cells/
Egle Therapeutics to Highlight Novel Preclinical Findings for Regulatory T Cells Targeting Programs...
Oct 6, 2025 - Egle Therapeutics to Highlight Novel Preclinical Findings for Regulatory T Cells Targeting Programs.
regulatory t cellsegle therapeuticshighlight
https://www.bioqubeventures.com/egle-therapeutics-raises-40-million-series-a/
Egle Therapeutics raises 40 million € Series A to develop First-In-Class T-regulatory cells...
Oct 6, 2025 - Egle Therapeutics SAS (Egle), an emerging biotechnology company announces that it has completed a €40M ($46.4M) Series A financing.
egle therapeuticsin class
https://www.bioqubeventures.com/egle-therapeutics-to-present-clinical-trial-progress/
Egle Therapeutics to Present Clinical Trial Progress Poster on Phase I/II EGL-121 Study for EGL-001...
Oct 6, 2025 - Egle Therapeutics announced a poster presentation at the upcoming 2025 American Society of Clinical Oncology (ASCO) Annual Meeting.
egle therapeuticsclinical trial
https://www.bioqubeventures.com/egle-therapeutics-strengthens-its-executive-leadership-team/
Egle Therapeutics Strengthens its Executive Leadership Team With the Appointment of Christophe...
Oct 6, 2025 - Egle Therapeutics announced the appointment of experienced biotechnology industry executive, Christophe Quéva, Ph.D., as Chief Executive Officer
executive leadership teamegle therapeutics